Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome

Agorastos, T.; Karavida, A.; Lambropoulos, Alexandros; Constantinidis, Theodore C.; Tzitzimikas, S.; Chrisafi, S.; Saravelos, H.; Vavilis, Dimitrios; Kotsis, A.; Bontis, J.

doi:10.1080/713605679

Cited by 11 publications

(19 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data relating to late pregnancy loss were extracted from 15 studies ( n = 4038) (Infante‐Rivard et al , 1991; Bocciolone et al , 1994; De Carolis et al , 1994; Yasuda et al , 1995; Gris et al , 1999; Meinardi et al , 1999; Rothbart et al , 1999; Bare et al , 2000; Kupferminc et al , 2000a; Martinelli et al , 2000; Pabinger et al , 2000; Alfirevic et al , 2001; Agorastos et al , 2002; Alonso et al , 2002; Many et al , 2002); significant associations were observed in carriers of heterozygous factor V Leiden (OR 2·06; 95% CI 1·10–3·86), heterozygous prothrombin (OR 2·66; 95% CI 1·28–5·53), protein S deficiency (OR 20·09; 95% CI 3·70–109·15) and anticardiolipin antibodies (OR 3·30; 95% CI 1·62–6·70) (Fig 6). No evidence of heterogeneity was observed.…”

Section: Resultsmentioning

confidence: 99%

Thrombophilia in pregnancy: a systematic review

et al. 2005

View full text Add to dashboard Cite

Summary Growing evidence suggests that thrombophilia is associated with venous thromboembolism (VTE) and adverse pregnancy outcomes. However, methodological limitations have made it difficult to obtain a clear overview of the overall risks. We conducted a systematic review to determine the risk of VTE and adverse pregnancy outcomes associated with thrombophilia in pregnancy. The effectiveness of prophylactic interventions during pregnancy was also evaluated. Major electronic databases were searched, relevant data abstracted and study quality assessed by two independent reviewers. Odds ratios (ORs) stratified by thrombophilia type were calculated for each outcome. A total of 79 studies were included in our review. The risks for individual thrombophilic defects were determined for VTE (ORs, 0·74–34·40); early pregnancy loss (ORs, 1·40–6·25); late pregnancy loss (ORs, 1·31–20·09); pre‐eclampsia (ORs, 1·37–3·49); placental abruption (ORs, 1·42–7·71) and intrauterine growth restriction (ORs, 1·24–2·92). Low‐dose aspirin plus heparin was the most effective in preventing pregnancy loss in thrombophilic women (OR, 1·62). Our findings confirm that women with thrombophilia are at risk of developing VTE and complications in pregnancy. However, despite the increase in relative risk, the absolute risk of VTE and adverse outcomes remains low. There is also a lack of controlled trials of antithrombotic intervention to prevent pregnancy complications. Thus, at present, universal screening for thrombophilia in pregnancy cannot be justified clinically.

show abstract

Section: Resultsmentioning

confidence: 99%

Thrombophilia in pregnancy: a systematic review

et al. 2005

View full text Add to dashboard Cite

show abstract

“…As shown in Figure , 477 articles were filtered after reviewing based on the exclusion criteria, including the title or abstract relevance to our study, is it possible to get full‐text, and does it exist detailed data. Finally, a total of 50 case–control studies(Table ) involving 6041 cases and 8364 controls were ultimately included in our meta‐analysis. All data were obtained from existing studies, with populations from Europe, the Middle East, North America, Latin America, Asia or Australia.…”

Section: Resultsmentioning

confidence: 99%

Association of hypertensive disorders of pregnancy risk and factor V Leiden mutation: A meta‐analysis

Ruan

2019

J of Obstet and Gynaecol

View full text Add to dashboard Cite

Aim To date, the conclusions of studies on a possible association between factor V Leiden (FVL, FV G1691A, rs6025) and hypertensive disorders of pregnancy (HDP) are conflicting. Here, we aimed to estimate the relationship between the risk of HDP and FVL. Methods Eligible studies focused on FVL and HDP were searched from the PubMed and the Web of Science databases up to March 31, 2018. We used random effects model for the meta‐analysis, and I2 statistic to assess the degree of heterogeneity between all included studies. To evaluate the association between FVL and the risk of HDP, we calculated the odds ratio (OR) and 95% confidence intervals (CI) comparing cases and controls of all samples and each subgroup based on different regions. Results Fifty citations on FVL and HDP were identified through the literature search, and a meta‐analysis on the GA + AA genotype between 6041 cases and 8364 controls was conducted. The holistic analysis found that pregnant women with GA or AA genotype of FVL have a 1.97‐fold (95% CI: 1.64–2.35, P < 0.00001) increased risk of HDP compared with GG carriers. While the OR are 2.23 (95% CI: 1.76–2.84, P < 0.00001) and 1.90 (95% CI: 1.12–3.23, P = 0.02) in Europe and the Middle East subgroups, respectively. Conclusion Factor V Leiden mutation is associated with an increased risk of HDP, and is particularly associated with preeclampsia and eclampsia in European women. However, further high‐quality studies are warranted to confirm the possible effectiveness of FVL in HDP patients.

show abstract

“…Despite the strong evidence for an association between inherited thrombophilia and adverse perinatal outcome, there is no consensus about which women should be tested and which tests must be done. 6…”

Section: Discussionmentioning

confidence: 99%

“…Genomic DNA was extracted from peripheral blood by a standard method. [2][3][4][5][6] The polymerase chain reaction (PCR) was used to assay the factor V Leiden mutation, the thermolabile methylene tetrahydrofolate reductase (MTHFR) C677T mutation and the prothrombin G20210A mutation. For factor V Leiden, amplification was performed using a mixture of 54 mM Tris HCl at pH 8.8, 5.4 mM MgCl 2 , 5.4 µM EDTA, 13.3 mM (NH 4 ) 2 SO 4 , 8% DMSO, 8 mM β-mercaptoethanol, 0.4 mg/ml BSA, 0.8 mM of each nucleoside triphosphate, 200 ng of each forward and reverse primer, 250 to 500 ng of genome DNA, and 2U Taq polymerase.…”

Section: Case Reportmentioning

confidence: 99%

Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations

et al. 2005

View full text Add to dashboard Cite

We describe a case of a pregnant woman who was found to be carrier of heterozygous factor V Leiden and prothrombin (FII) G20210A mutations. Five years before pregnancy she had had an episode of extensive deep venous thrombosis in the ileofemoral region, while using hormonal contraceptives. Anticardiolipin antibody (ACA), lupus anticoagulant and deficiencies of protein C, protein S and antithrombin III were evaluated by means of enzyme-linked immunosorbent assay (ELISA), dilute Russell Viper Venom time (dRVVT), coagulometric and chromogenic methods. Deoxyribonucleic acid (DNA) was amplified using the polymerase chain reaction (PCR) to study the factor V Leiden and G20210A mutations in the prothrombin gene and C677T mutation in the methylene tetrahydrofolate reductase (MTHFR) gene. In the sixth week of her first pregnancy, she developed another episode of deep venous thrombosis in the femoropopliteal veins of the right leg. She was treated with low-molecular weight heparin (nadroparin) until parturition (0.3 ml or 2,850 UI/day). The pregnancy evolved without any significant obstetric morbidity. The patient delivered a healthy baby by cesarean section. During the puerperium, she used prophylactic doses of nadroparin for (0.3 ml or 2,850 UI/day) six weeks and had no complications. We suggest that women who have an association of thrombophilia factors and a prior episode of venous thromboembolism must have antepartum anticoagulation management using unfractioned or low-molecular weight heparin and postpartum management using low-molecular weight heparin or oral anticoagulants. Anticoagulation is recommended during pregnancy because the real magnitude of the risk of major and life-threatening thromboembolic events in these women is unknown.

show abstract

Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome

Cited by 11 publications

References 0 publications

Thrombophilia in pregnancy: a systematic review

Thrombophilia in pregnancy: a systematic review

Association of hypertensive disorders of pregnancy risk and factor V Leiden mutation: A meta‐analysis

Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations

Contact Info

Product

Resources

About